Answers are grounded in this paper and cite their sources.
Tardive dyskinesia, like several other choreiform disorders, is felt to be primarily related to dopaminergic activity within the striatum. Physostigmine has been demonstrated to improve the abnormal movements in patients with tardive dyskinesia while scopolamine tends to aggravate abnormal movements and in some cases elicits abnormal movement not previously observed. This evidence supports the hypothesis that anticholinergic therapy in patients prone to develop tardive dyskinesia may increase the incidence of this disorder by lowering the threshold for the appearance of these movements.
No takes yet. Share an insight, caveat, or question.
Klawans et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: